Quick Answer
Kalaris Therapeutics, Inc. reported Stockholders Equity of $78.81 million for fiscal year 2025.
Kalaris Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $78.81M | +181.6% |
| 2024 | -$96.62M | -114.6% |
| 2023 | -$45.02M | -120.1% |
| 2022 | $224.52M | -0.3% |
| 2021 | $225.27M | -36.2% |
| 2020 | $353.06M | +785.5% |
| 2019 | -$51.50M | -68.2% |
| 2018 | -$30.62M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $41.87M | +146.8% | -21.2% |
| June 30, 2025 | $53.12M | +203.1% | -16.8% |
| March 31, 2025 | $63.87M | +234.4% | +166.1% |
| December 31, 2024 | -$96.62M | -114.6% | -8.1% |
| September 30, 2024 | -$89.38M | -145.8% | -73.5% |
| June 30, 2024 | -$51.53M | -122.5% | -8.4% |
| March 31, 2024 | -$47.54M | -124.6% | -5.6% |
| December 31, 2023 | -$45.02M | -120.1% | -123.0% |
- Kalaris Therapeutics, Inc. showed an increase of +181.6% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Kalaris Therapeutics, Inc.’s stockholders equity has grown by 357.4% (from -$30.62 million to $78.81 million).
- The most recent figure is from Kalaris Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: